<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Commonly used, oral and transdermal, long-acting pure mu-opioid agonists for chronic pain in adults (refer to notes)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Commonly used, oral and transdermal, long-acting pure mu-opioid agonists for chronic pain in adults (refer to notes)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Commonly used, oral and transdermal, long-acting pure mu-opioid agonists for chronic pain in adults (refer to notes)</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="12%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Brand name<br/> (United States)</td> <td class="subtitle1">Sample initial dose in opioid-tolerant adults</td> <td class="subtitle1">Serum half-life<br/> (hours)</td> <td class="subtitle1">Duration of analgesic effect<br/> (hours)</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Oral, long-acting preparations</td> </tr> <tr> <td class="indent1" rowspan="2">Hydrocodone</td> <td>Hysingla ER</td> <td>20 mg orally every 24 hours</td> <td>7 to 9</td> <td>24</td> <td rowspan="2"> <ul> <li>Use a reduced dose in kidney and/or hepatic impairment</li> <li>May interact with drugs that alter CYP3A4 and CYP2D6 metabolism*</li> <li>Converted to active metabolite by CYP2D6, which is subject to polymorphisms; individual effects vary</li> <li>Hysingla ER and Zohydro ER have abuse-deterrent<sup>¶</sup> properties</li> </ul> </td> </tr> <tr> <td>Zohydro ER (brand not available; generic only)</td> <td>10 mg orally every 12 hours</td> <td>13</td> <td>≤12 in patients with non-cancer back pain</td> </tr> <tr> <td class="indent1" rowspan="2">Hydromorphone</td> <td>Exalgo</td> <td>8 mg orally every 24 hours</td> <td>11</td> <td>24</td> <td rowspan="2"> <ul> <li>Use a reduced dose in kidney and/or hepatic impairment</li> <li>Non-CYP metabolism (ie, glucuronidation) may be an advantage for patients receiving drugs that significantly alter CYP3A4 metabolism</li> <li>Exalgo has abuse-deterrent<sup>¶</sup> properties</li> </ul> </td> </tr> <tr> <td>Hydromorph Contin (available in Canada)</td> <td>3 mg orally every 12 hours</td> <td>Not specified</td> <td>≥12</td> </tr> <tr> <td class="indent1" rowspan="2">Morphine</td> <td>MS Contin</td> <td>15 mg orally every 8 or 12 hours</td> <td>Not specified</td> <td>8 to 12</td> <td rowspan="2"> <ul> <li>Active metabolites are dependent on kidney function for clearance; avoid or use a reduced dose frequency in organ dysfunction</li> <li>Accumulation of metabolite may contribute to hyperalgesia or other neurotoxicity</li> <li>Non-CYP metabolism (ie, glucuronidation) may be an advantage for patients receiving drugs that significantly alter CYP3A4 metabolism</li> <li>May interact with drugs that inhibit P-glycoprotein (P-gp) efflux*</li> <li>Capsule (Kadian) may be opened and sprinkled on soft food for immediate swallowing</li> </ul> </td> </tr> <tr> <td>Kadian (brand not available; generic only)</td> <td>30 mg orally daily in 1 or 2 divided doses</td> <td>11 to 13</td> <td>12 to 24</td> </tr> <tr> <td class="indent1" rowspan="2">Oxycodone</td> <td>OxyContin</td> <td>10 mg orally every 12 hours</td> <td>4.5</td> <td>8 to 12</td> <td rowspan="2"> <ul> <li>Use a reduced dose in kidney and/or hepatic impairment.</li> <li>May interact with drugs that alter CYP3A4 metabolism*.</li> <li>OxyContin has abuse-deterrent<sup>¶</sup> properties.</li> <li>Xtampza ER has abuse-deterrent<sup>¶</sup> properties; capsule may be opened and sprinkled on soft food for immediate swallowing.</li> <li>Xtampza ER doses are expressed as oxycodone <strong>base</strong>. 9 mg oxycodone base is equivalent to 10 mg oxycodone hydrochloride (OxyContin).</li> </ul> </td> </tr> <tr> <td>Xtampza ER</td> <td>9 mg orally every 12 hours</td> <td>5.6</td> <td>≤12</td> </tr> <tr> <td class="indent1">Oxymorphone</td> <td>Generic only</td> <td>5 mg orally every 12 hours</td> <td>9 to 11</td> <td>12</td> <td> <ul> <li>Use a reduced dose in kidney and/or hepatic impairment</li> <li>Take on empty stomach</li> <li>Opana ER brand, an abuse-deterrent formulation, was withdrawn from the United States market in mid-2017 due to concerns related to IV injection abuse, including reports of thrombotic microangiopathy; generic extended-release preparations of oxymorphone remain available</li> </ul> </td> </tr> <tr> <td class="indent1">Tapentadol</td> <td>Nucynta ER</td> <td>50 mg orally every 12 hours</td> <td>5 to 6</td> <td>12</td> <td> <ul> <li>Inhibits norepinephrine reuptake</li> <li>Avoid in patients with severe kidney impairment (CrCl &lt;30 mL/minute)</li> <li>Use a reduced dose in moderate liver dysfunction, avoid use with severe hepatic dysfunction</li> <li>Risk for serotonin syndrome in patients using MAOI, SSRI, SNRI, and TCA medications</li> <li>Generally reserved for third-line use</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="6">Transdermal</td> </tr> <tr> <td class="indent1">Fentanyl</td> <td>Duragesic</td> <td>12 or 25 mcg per hour, patch applied every 72 hours</td> <td>20 to 27 following patch removal</td> <td> <p>48 to 72</p> Some analgesic effect may persist following patch removal due to continued absorption from skin</td> <td> <ul> <li>Use a reduced dose in kidney and/or hepatic impairment</li> <li>May interact with drugs that alter CYP3A4 metabolism*</li> <li>Onset of analgesic effect is delayed 12 to 24 hours after initial application</li> <li>Approximate dose conversions for fentanyl transdermal and commonly used oral opioids are provided as a separate table in UpToDate</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>NOTES:</strong>
<ul>
<li>The total daily dose requirement for a long-acting opioid formulation should be established first with the use of an appropriate immediate-release opioid analgesic. Details for initiating and adjustment of dose vary by each agent. Refer to UpToDate reviews on chronic non-cancer and cancer pain management with opioids and individual drug monographs (ie, Lexicomp) for detailed information on individual agents.</li>
<li>Opioids have similar equianalgesic potency whether administered as an immediate-release form (ie, smaller, more frequently divided doses) or an extended-release preparation. To convert from an oral immediate-release to an extended-release preparation of the same opioid, use the sum of the doses of the immediate-release form administered during the usual interval of the extended-release form. As an example, morphine sulfate immediate-release 30 mg orally every 4 hours (total of 180 mg per day) may be converted to morphine sulfate extended-release 60 mg orally every 8 hours (total of 180 mg per day).</li>
<li>Approximate equianalgesic dose equivalents and information on oral immediate-release and parenteral pure mu-opioid agonists that are commonly used in management of chronic non-cancer and cancer-related pain are provided as separate tables within UpToDate.</li>
</ul></div><div class="graphic_footnotes"><p>CYP3A4: cytochrome P450 3A4; CYP2D6: cytochrome P450 2D6; IV: intravenous; mcg: microgram; ER: extended-release; P-gp: P-glycoprotein; MAOI: monoamine oxidase inhibitor; SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor; TCA: tricyclic antidepressants; CrCl: creatinine clearance.</p>
<p>* Lists of drugs that alter CYP3A4 metabolism or P-gp multidrug efflux transporter (ie, inhibitors and inducers) are available as separate tables in UpToDate. To determine drug interactions and management suggestions for specific combinations, use the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included within UpToDate.</p>
¶ Abuse-deterrent formulations have 1 or more properties that make intentional manipulation of the dose form more difficult (eg, resistant to crushing and dissolution) or less likely to produce an opioid effect (eg, altered to minimize absorption through nasal mucosa). No oral opioid formulation prevents ingestion of an excessive dose.</div><div class="graphic_reference"><p>Courtesy of Kathleen Broglio, DNP, MN, ANP-BC, ACHPN and Russell K Portenoy, MD.</p>
Additional data from:
<ol>
<li>National Comprehensive Cancer Network. Adult Cancer Pain, Version 2.2016.</li>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
</ol></div><div id="graphicVersion">Graphic 111207 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
